Skip to main content

Table 3 Timing of assessments of endpoints for efficacy and safety

From: Study on psychoeducation enhancing results of adherence in patients with schizophrenia (SPERA-S): study protocol for a randomized controlled trial

 

T0

T1

T2

T3

Background information (age, sex, diagnosis, and so on)

X

   

Clinical Global Impressions

X

X

X

X

Brief Psychiatric Rating Scale (BPRS)

X

X

X

X

Positive And Negative Syndrome Scale (PANSS)

X

X

X

X

Social Performance Scale

X

X

X

X

Health of the Nation Outcome Scales (HoNOS)

X

X

X

X

World Health Organization Quality Of Life (WHOQoL)

X

X

X

X

The Family Questionnaire

X

X

X

X

Medication Adherence Rating Scale

X

X

X

X

Brief Adherence Rating Scale

X

X

X

X

Dosage Record and Treatment Emergent Symptoms Scale (DOTES)

X

X

X

X

Sheenan-Suicidality Tracking Scale (S-STS)

X

X

X

X

Modified Overt Aggression Scale (MOAS) 1.0

X

X

X

X

Blood sample for assessing of the blood level of the prescribed drug

X

X

X

X

Assessment of blinding

   

X